NIH Funded Research

Drug Disposition in Liver Transplant Patients

NIH
12/1988 – 11/1991
$562,486
Co-investigator (PI: Gilbert J. Burckart)

Predicting Outcome in Alcoholic Liver Transplant Recipient

NIH K08AA00257/01
June 1998-May 2003
$659,791
Consultant (PI: Andrea DiMartini)

Pharmaceutical Industry Sponsored Research

Clinical Trial of FK 506 in Liver and Renal Transplant Patients

Fujisawa Pharmaceuticals
10/1988 to 9/1990
$90,000
Co-investigator (PI: Starzl)

Interaction of FK 506 and Fluconazole

Pfizer Pharmaceuticals
6/1992 to 5/1993
$100,000
Co-investigator (PI: Venkataramanan)

Recent Clinical Trials

Multicenter trial in Entercavir v/s Adefovir

Bristol-Myer Squibb
$72,000
Principal Investigator

Pharmacokinetics Study with Valganciclovir

Roche
$115,652
Principal Investigator

Phase IIB Study of ISA247 and Tacrolimus

Isotechnika Inc.
$197,613
Principal Investigator

Fujisawa Research Program

FK 506 Kinetics in Patients with Liver Disease

Fujisawa Pharmaceuticals
1994-1997
$75,621
Co-investigator (PI: Venkataramanan)

FK 506 Studies-Data Analysis

Fujisawa Pharmaceuticals
1995
$10,000
Co-investigator (PI: Venkataramanan)

Long-Term Results of Pediatric Liver Transplantation

Fujisawa
1998
$10,000
Co-PI (PI: Jorge Reyes)

Clinical Research Studies

Open Label Study of Neoral as Primary Immunsuppressant Therapy

Novartis Pharmaceuticals
1/1998-12/1999
$83,200
Principal Investigator

CellCept Study in Post-Liver Transplant Patients

Roche Pharmaceuticals
12/1998-12/2000
$141,627
Principal Investigator

Sirolimus for Primary Pancreatic Transplantation

Wyeth
$5,000
Principal Investigator